Fusion proteins comprising immunoglobulin constant domain-derived scaffolds
AssigneeResearch Corporation Technologies, Inc.
InventorsDavid Bramhill, Kurt R. Gehlsen
Life of this patent
Estimating the term…
Loading patent…
AssigneeResearch Corporation Technologies, Inc.
InventorsDavid Bramhill, Kurt R. Gehlsen
Estimating the term…
This disclosure features fusion proteins comprising a base protein linked to or incorporated in a CH2 scaffold of IgG. The CH2 scaffold can derive from the macaque CH2 domain of IgG. The fusion proteins can effectively bind a single or multiple targets, and can be engineered to regulate effector functions as desired. The fusion proteins can have an increased serum half-life, solubility, stability, protease resistance, and/or expression as compared to the scaffolds alone and/or as compared to the base protein alone. This disclosure also features fusion proteins comprising a base protein, a CH2 scaffold and a discrete polyethylene glycol (dPEG) linked to the scaffold via a serine, tyrosine, cysteine, lysine, or a glycosylation site of the scaffold. This disclosure additionally features scaffolds linked to a discrete polyethylene glycol (dPEG) via a serine, tyrosine, cysteine, or lysine of the scaffolds or a glycosylation site of the scaffold.
A CH2 scaffold comprising the amino acid sequence set forth in SEQ ID NO:
A CH2 scaffold comprising the amino acid sequence set forth in SEQ ID NO:
A CH2 scaffold comprising the amino acid sequence set forth in SEQ ID NO:
A CH2 scaffold, comprising the amino acid sequence set forth in SEQ ID NO:
A CH2 scaffold comprising the amino acid sequence set forth in SEQ ID NO:
A CH2 scaffold comprising the amino acid sequence set forth in SEQ ID NO:
A CH2 scaffold comprising the amino acid sequence set forth in SEQ ID NO:
Dependencies are inferred from the claim text.